LRMR - NASDAQ
Larimar Therapeutics, Inc.
$3.30
-3.0%Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
At a Glance
Live SnapshotLarimar Therapeutics, Inc. Management Team
Dr. Gopi Shankar M.B.A., Ph.D.
Chief Development Officer
Compensation
$618,664
Dr. Carole S. Ben-Maimon M.D.
Chief Executive Officer, President & Director
Compensation
$905,658
Dr. Russell G. Clayton Sr., D.O, D.O.
Chief Medical Officer
Mr. Michael Celano CPA
Secretary & Chief Financial Officer
Compensation
$625,729
Mr. Francis Michael Conway CPA
Vice President & Controller
Mr. John Berman
Vice President of Finance & Administration
Ms. Jennifer Spokes Johansson
Vice President of Legal & Compliance
Larimar Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $13.74M worth of LRMR shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
1.1M
5.42M
0
0.00
+5.4M
+$5.42M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
2.6M
8.32M
0
0.00
+8.3M
+$8.32M
Top Buyers
Flynn James E
Director, 10 Percent Owner, Other: * Director By Deputization
$13.74M
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $13.74M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
LRMR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | April 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 11, 2025 | April 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 11, 2023 | May 09, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 12, 2022 | May 10, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 14, 2021 | May 12, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | August 19, 2020 | September 29, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 26, 2019 | June 13, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 18, 2018 | June 06, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 21, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.